Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

To assess the effects of vitamin D3 compounds on intestinal FCA and calcium-regulating hormones in post-menopausal osteoporosis, a randomized open-label prospective study was conducted.

Who Took Part

By PubMed's age tags, the people studied were older adults, women only.

Intestinal fractional calcium absorption (FCA) was assessed before and after vitamin D3 treatment.

How the Study Was Run

The design is described as randomized and open-label.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Vitamin D, K2, Magnesium and Zinc was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

What Was Measured

PubMed files the paper under topics including Bone Density Conservation Agents, Calcitriol, Calcium, Cholecalciferol, Hydroxycholecalciferols, Intestinal Absorption and Osteoporosis, Postmenopausal.

Author keywords: Alfacalcidol, Eldecalcitol, Intestinal calcium absorption, Plain vitamin D3 and Serum vitamin D concentration.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.